

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Life Sciences Research Partners vzw	01/31/2012
RECEIVING PARTY DATA	
Name:	Katholieke Universiteit Leuven, K.U.Leuven R&D
Street Address:	Waaistraat 6, Box 5105
City:	Leuven
State/Country:	BELGIUM
Postal Code:	B-3000
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12377048
CORRESPONDENCE DATA	
Fax Number:	(617)428-7045
Phone:	(617)428-0200
Email:	patentadministrator@clarkelbing.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	James D. DeCamp
Address Line 1:	Clark & Elbing LLP
Address Line 2:	101 Federal Street
Address Line 4:	Boston, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	50304/214001
NAME OF SUBMITTER:	Jan N. Tittel
Total Attachments: 2 source=50304_214001_CoApplicant_Agreement#page1.tif source=50304_214001_CoApplicant_Agreement#page2.tif	

CH \$40.00 12377048

CO-APPLICANT AGREEMENT

We, Life Sciences Research Partners vzw
with principal place of business at
Herestraat 49, bus 913
B-3000 Leuven
Belgium

as represented by *Raymond De Boeck*

do herewith assign part of the rights and duties to these AU, CA and US patent applications:

- 1) AU2007283731 filed on August 13, 2007 and entitled "Immunogenic peptides and their use in immune disorders"
- 2) AU2008350785 filed on February 14, 2008 and entitled "Immunogenic peptides and their use in transplantation"
- 3) AU2009214038 filed on February 16, 2009 and entitled "Elimination of immune responses to viral vectors"
- 4) AU2009214039 filed on February 16, 2009 and entitled "Immunogenic control of tumours and tumour cells"
- 5) AU2009214040 filed on February 16, 2009 and entitled "Strategies to prevent and/or treat immune responses to soluble allofactors"
- 6) AU2009214041 filed on February 16, 2009 and entitled "cd4+ t-cells with cytolytic properties"
- 7) AU2009214042 filed on February 16, 2009 and entitled "Immunotherapy targeting intracellular pathogens"
- 8) CA2660605 filed on August 13, 2007 and entitled "Immunogenic peptides and their use in immune disorders"
- 9) CA2715517 filed on February 14, 2008 and entitled "Immunogenic peptides and their use in transplantation"
- 10) CA2715484 filed on February 16, 2009 and entitled "Elimination of immune responses to viral vectors"
- 11) CA2715488 filed on February 16, 2009 and entitled "Immunogenic control of tumours and tumour cells"
- 12) CA2724440 filed on February 16, 2009 and entitled "Strategies to prevent and/or treat immune responses to soluble allofactors"
- 13) CA2715536 filed on February 16, 2009 and entitled "cd4+ t-cells with cytolytic properties"
- 14) CA2715611 filed on February 16, 2009 and entitled "Immunotherapy targeting intracellular pathogens"
- 15) US 12/377048 filed on August 13, 2007 and entitled "Immunogenic peptides and their use in immune disorders"

with part of all its rights and duties

to

Katholieke Universiteit Leuven

K.U.Leuven R&D
with principal place of business at
Waaistraat 6, Box 5105
B-3000 Leuven
Belgium

Dr. Patrick CHALTIN
IPR Officer

Paul VAN DUN
General Manager


as represented by

who declares to accept part of the ownership of these AU, CA and US patent applications with part of all its rights and duties.

For:

Life Sciences Research Partners VZW

signature



name: Raymond De Bonolt


capacity: Director

date: 31.1.2012

For:

Katholieke Universiteit Leuven

signature



name:

Dr. Patrick CHALTIN
capacity: IPR Officer

date:

8 Feb 2012



Paul VAN DUN
General Manager